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Trimethoprim-sulfamethoxazole (TMP-SMX, co-trimoxazole, or bactrim) has been the standard ﬁrst-line
treatment against Pneumocystis jirovecii pneumonia (PCP) for decades. However, adverse effects and
cases of treatment failure have led to a search for alternative agents. We present a case of a 50 year old
immune compromised female whose course of PCP did not improve until Caspofungin was added to TMPSMX.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction
Initially classiﬁed as a protozoa, Pneumocystis was later
identiﬁed as a member of ascomycetous fungi based on ribosomal
RNA sequencing in the 19800 s [1].
About eighty percent of children are exposed to this ubiquitous
organism by two to three years of age but its virulence is low, often
causing no more than colonization. Even in the immunocompromised host pneumocystis pneumonia often presents as a mild,
insidious and nonspeciﬁc illness but can lead to respiratory failure
and death [2].
Trimethoprim-sulfamethoxazole is effective for both prophylaxis and treatment of PCP [3,4]. It is not, however, without
adverse effects and hypersensitivity reactions are particularly
common in patients with HIV compared to those without HIVup to two thirds of individuals versus one in twenty, respectively.
Other adverse reactions include rash, cytopenia, nausea, vomiting, and metabolic derangements such as hyperkalemia,
hyponatremia and acidosis. Intolerance leads to discontinuation
in up to half of patients with HIV [5]. In addition, there is concern
for developing antibiotic resistance. The sulfamethoxazole
component, an analog of para-aminobenzoic acid, competitively
binds to dihydropteroate synthetase (DHPS), blocking an
intermediate step in the production of tetrahydrofolate needed
for DNA synthesis. Mutations in this enzyme and not dihydrofolate reductase (DHFR), the site of action for the trimethoprim
component of co-trimoxazole, is associated with prior use of cotrimoxazole and dapsone [6,7]. Whether or not this translates to
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poor clinical outcomes is not clear. A systematic review
published in 2004 and other studies since then have either
not shown or not concurred on an association between DHPS
mutations and treatment failure [8–12]. Regardless, the adverse
effects of co-trimoxazole along with a limited number of
effective alternatives highlight the need for further drug
investigation. Current alternative options include clindamycin
plus primaquine, pentamidine, atovaquone, and trimethoprim
plus dapsone. Only the ﬁrst two options are recommended for
cases of severe PCP, however, and the toxicity of intravenous
pentamidine makes it a less desirable choice. [2] A meta-analysis
of salvage therapy for PCP concluded that clindamycin plus
primaquine is the preferred alternative therapy to TMP-SMX due
to its high efﬁcacy of 88–92% [13].
Echinocandins, caspofungin in particular, have also shown
some promise against Pneumocystis. Unlike most fungi, Pneumocystis lacks ergosterol which is normally an integral component of
the fungal cell membrane and thus, azole and polyene therapies
are ineffective. The organism does, however, produce and depend
upon beta-D Glucan in its cell wall which can be targeted by
echinocandins. Prospective randomized trials are lacking but
several case reports have shown success with caspofungin in
treating severe refractory PCP either as monotherapy or combined
with traditional agents [14–17].
Case report
A 50-year-old female on prednisone of 60 mg daily for Sjogren’s
syndrome was diagnosed with Diffuse Large B-Cell Lymphoma in
May 2016. In addition, she had Mikulicz syndrome, Mixed
Connective Tissue disease, Antiphospholipid syndrome and factor
V Leiden deﬁciency. She was planned for initiation of RCHOP but
presented with a new cough, dyspnea, fevers and bilateral ground
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Fig. 1. CT chest on admission showing scatter bilateral groundglass opacities.

glass opacities on chest CT (Fig. 1). Broad spectrum antibiotics were
administered for pneumonia and after three days she transferred
hospitals for chemotherapy. Bactrim at treatment dose was
promptly begun after transfer for possible PCP and Prednisone
was increased to 100 mg daily for chemotherapy. She had been
taking a prophylactic dose of Bactrim for only two days prior to
presentation. By day seven she was sent to the intensive care
monitoring for worsening hypoxia and underwent a bronchoscopy
which conﬁrmed pneumocystis organisms on cytopathology. BAL
cultures including for acid fast organisms, blood cultures, common
respiratory viral PCR testing and HIV screening were all negative.
Despite two weeks of appropriate therapy with clinical improvement permitting Prednisone to be tapered to 40 mg daily, she had
recurrence of fevers, worsening hypoxemia and progression of
bilateral patchy opacities on chest radiograph (Fig. 2). Due to poor
clinical response without an alternative diagnosis, she underwent
a second bronchoscopy which demonstrated organizing pneumonia on pathology associated with Pneumocystis carinii infection.
Intravenous caspofungin was then added to her regimen, 70 mg
followed by 50 mg every 24 h. Slowly she began to improve on both
bactrim and caspofungin and was eventually transferred to

medical wards after one week of combination therapy. She
received a total of two weeks of caspofungin and six weeks of
intravenous TMP-SMX. Her bilateral opacities improved (Fig. 3)
and she was discharged home on secondary oral prophylaxis and a
steroid taper.
Discussion
Our patient had at least a few risk factors for developing
pneumocystis pneumonia including use of high-dose corticosteroids, hematologic malignancy and inﬂammatory rheumatologic
conditions. In addition, she also had risk factors for poor outcome:
low hemoglobin, elevated LDH levels despite treatment, poor
oxygenation and low albumin. Although the mortality rate among
HIV patients with PCP has decreased signiﬁcantly with the advent
of antiretroviral therapy, patients such as ours who are not infected
with HIV continue to face a 30–50% mortality rate [2]. The need for
new, efﬁcacious, and safe agents against PCP is made apparent in
this patient population.
Pneumocystis produces 1-3-beta-D-glucan, an essential component of its fungal cell wall in the cystic form and thus, a potential

Fig. 2. CT chest after two weeks of Bactrim therapy showing progression of bilateral consolidations with airbronchograms compatible with extensive multifocal pneumonia.
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Fig. 3. CT chest after 6 weeks of PCP treatment showing decreased bilateral groundglass opacities and dense consolidations.

target for echinocandin therapy. Rodent models have demonstrated
the efﬁcacy of echinocandins in enhancing survival, reducing cyst
burden and preventing pathogen transmission [18,19]. Case reports,
however, demonstrated inconsistent results. Hong et al reported four
cases of HIV-negative patients from Seoul, South Korea who did not
respond with caspofungin as salvage therapy, three of whom died
from complications of their infection [20]. Kamboj et al described
two patients from Memorial Sloan Kettering Cancer Center with
hematologic malignancies who each died while on combination
therapy - one with bactrim and micafungin, the other with
caspofungin and intravenous pentamidine [21].
For our patient, however, the addition of caspofungin was the
turning point in her course and others have had similar results. Tu
et al reported three renal transplant patients in China who received
the same combination therapy for PCP and were successfully
weaned off either mechanical or noninvasive ventilation [22]. An
AIDS patient in Taiwan had complete recovery from PCP with
caspofungin after bactrim was discontinued due to adverse effects
of rash and leukopenia [17]. Li et al described a case of caspofungin
plus clindamycin successfully treating PCP in a patient with IgA
nephropathy who did not tolerate bactrim due to oral ulcerations
and hemorrhages [14]. The discrepancy between case reports may
be due to difference in immune suppression and unclear risk
factors for poor outcome including DHPS mutations. Randomized
control trials will be necessary to clarify the role of echinocandins
in treatment regimens for PCP.
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